Intrauterine contraception

October 2014
Nursing Standard;10/15/2014, Vol. 29 Issue 7, p19
Trade Publication
The article presents an overview of intrauterine contraception methods, which are long acting reversible contraceptives which include copper intrauterine devices and levonorgestrel intrauterine systems, and discusses their risks and side effects. A discussion of resources which offer additional information on intrauterine contraception , and of strategies that nurses can use to help their patients on intrauterine contraception, is presented.


Related Articles

  • Special considerations when providing contraception advice and information to young people. Dixon, Vicky // British Journal of School Nursing;May2014, Vol. 9 Issue 4, p170 

    School nurses are in an ideal position to educate young people about the different methods of contraception available, which includes emergency contraception. There are 15 different contraceptive options in the UK, 13 of which are reversible and therefore potentially suitable for young people. A...

  • Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Sivin, Irving // Drug Safety;Mar2003, Vol. 26 Issue 5, p303 

    Levonorgestrel-releasing implants are long acting contraceptives, approved for 5 years of continuous use. Two marketed systems, the six capsule Norplant[sup ®] and the two rod Jadelle[sup ®], have essentially equal rates of drug release, pregnancy and adverse events over 5 years of use....

  • Levonorgestrel Subdermal Implants: A Review of Contraceptive Efficacy and Acceptability. Coukell, A.J.; Balfour, J.A. // Drugs;Jun1998, Vol. 55 Issue 6, p861 

    Levonorgestrel 6-capsule subdermal implants (Norplant) are an effective form of reversible contraception. When implanted under the skin of the upper arm, they release drug into the circulation at a relatively constant rate over 5 years. Generally, the cumulative pregnancy rate at the end of 5...

  • ellaOne is more effective at preventing pregnancies.  // Practice Nurse;2/12/2010, Vol. 39 Issue 3, p8 

    The article focuses on a study published in "The Lancet," which found that the new emergency contraceptive pill ellaOne (ulipristal acetate) prevents more pregnancies than the widely used alternative, levonorgestrel.

  • Levonorgestrel--Implant.  // Drugs in R&D;2002, Vol. 3 Issue 6, p398 

    Adis Comments Levonorgestrel-releasing Norplant contraceptive implants have a recorded history of successful use by more than 200 000 women in 30 countries. The original system (Norplant-6), developed by the Population Council, comprises a set of six capsules each containing 36mg of...

  • Mirena. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p510 

    An encyclopedia entry for Mirena is presented. It is a brand-name intrauterine contraceptive device that contains the female hormone levonorgestrel. It is fitted inside the uterus which then released a low dose of the drug continually. It may cause irregular bleeding or slightly heavier...

  • Users' Perspectives on Bleeding Patterns after Two Years of Levonorgestrel-Releasing Intrauterine System Use. Nascimento, R.; Bahamondes, L.; Hidalgo, M.; Perrotti, M.; Espejo-Arce, X.; Petta, C.A. // Drugs in R&D;2002, Vol. 3 Issue 6, p387 

    Deals with a study which evaluated the perspectives of users of the levonorgestrel-releasing intrauterine system in Campinas, Brazil. Materials and methods; Results; Discussion; Conclusions.

  • Advance provision of EC leads to best outcomes.  // Pharmacy Today;Mar2007, Vol. 13 Issue 3, p2 

    The article reports on the findings of the study concerning the best outcomes of emergency contraceptive (EC) in the U.S. It reveals that women who obtain levonorgestrel with advance access are likely to take the medication within 24 hours of unprotected sex twice and more than four times likely...

  • Advisory for Norplant Contraceptive Kits.  // FDA Consumer;Sep/Oct2002, Vol. 36 Issue 5, p6 

    Reports on the discontinuation of Norplant capsules, an implant contraception system. Use of levonorgestrel implants; Limitations in product component supplies; Advice from the US. Food and Drug Administration for women that use the system.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics